News & Trends - MedTech & Diagnostics
Urgent measures to ensure the continuing availability of essential medical devices
MedTech News: The Biomedical Alliance in Europe, representing 36 medical and research societies, is calling on Member States to take action and prevent a potential shortage of medical devices on the implementation of the Medical Devices Regulation.
Doctors and scientists across all medical specialties strongly support the aim of the EU Medical Device Regulation (EU 2017/745) (MDR) which has applied since May 2021, to improve the standards of clinical evidence for high-risk medical devices.
Unfortunately, there is a chance that essential medical devices may disappear from the market. Contributory causes include the fact that that the personnel and resources that were envisaged to be needed in order to deliver the requirements of the new Regulation have never been allocated within the European Commission, and that the capacity of the notified bodies to approve devices remains insufficient. It is increasingly apparent that there is a real risk that many medical devices may be taken off the market by manufacturers and become unavailable for patients who require them, unless special measures are taken urgently to avoid this.
Top trends shifting the future of the medtech sector – Cardinal Health global leader
Medical device manufacturers reported from a recent survey, that 27% of all medical devices may be made obsolescent or discontinued. Notified bodies announced that new certificates of approval have been issued for only 1,069 devices out of a total of around 25,000 that need to be certified under the MDR.
Medical devices for orphan or paediatric indications are particularly vulnerable to additional regulatory costs or delays, and although there is no European database to identify these products, the loss of even a small number of products can have major implications for health care across Europe.
This problem was discussed by Ministers of Health in the EU at the meeting of the Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) on 14 June 2022. The BioMed Alliance urges ministers to propose new measures to ensure that devices can remain available for patients.
The members of the Alliance will support the European Commission in developing and implementing policies to prevent what could become a major clinical crisis.
Medical
NSW Health to settle ‘largest’ class action
A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]
MoreNews & Trends - Pharmaceuticals
Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap
Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]
MoreNews & Trends - Pharmaceuticals
AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases
Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]
MoreNews & Trends - Pharmaceuticals
PBAC recommendation to reshape prescribing in heart failure
Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]
More